Article
Mutagenicity studies of benzalazine.
Arzneimittel-Forschung - 1 Dec 1994
Herzog R, Leuschner J
Abstract excerpt
Benzalazine (2-hydroxy-5-[(4-carboxyphenyl) azo] benzoic acid, CAS 64896-26-0), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, was studied for genotoxic effects by using the following short-term in vitro and in vivo test: 1. reverse mutation test (Ames method) on Salmonella typhimurium, 2. HGPRT (hypoxanthine-guanine phosphoribosyl transferase) point mutation test...
Topics
- Animals
- Benzaldehydes
- Cell Line
- Cricetinae
- Cricetulus
- Female
- Hydrazones
- Hypoxanthine Phosphoribosyltransferase
- In Vitro Techniques
- Male
- Metaphase
- Mutagenicity Tests
